BioSpace News Archive

Pfizer Inc. announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common Stock of record at the close of business on July 30, 2021.

Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug and Administration has maintained Priority Review for the Company’s Abbreviated New Drug Application for vasopressin.

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that LYNPARZA has been granted conditional approval in China as monotherapy for the treatment of adult patients with germline or somatic BRCA-mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment that included a new hormonal agent.

Allergy Therapeutics plc, the fully integrated commercial biotechnology company specialising in allergy immunotherapy, announces a pre-close trading update for the year ended 30 June 2021.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced results from the company’s Phase 2b trial, ReDUX4, in people with facioscapulohumeral muscular dystrophy.

Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives, announced the pricing of its initial public offering of 4,800,000 shares of common stock at a price to the public of $9.00 per share.

ObsEva SA announced the presentation of data from two of its clinical development programs at the European Society of Human Reproduction and Embryology Virtual 37th Annual Meeting, being held June 26 - July 1, 2021.

Pratteln, Switzerland, and Rockville, MD, USA,June 24, 2021 – Santhera Pharmaceuticals and ReveraGen BioPharma, Inc announce presentations of the positive and statistically highly significant topline results from the VISION-DMD study at the Parent Project Muscular Dystrophy 2021 Virtual Annual Conference.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, announces that it has successfully renegotiated and unwound its earlier license agreements with the Alter Pharma Group.

Erectile dysfunction shockwave therapy is a non-invasive therapeutic technique used for the treatment of erectile dysfunction.